Hatipoglu Betul, Benedetti Enrico, Oberholzer José
Division of Transplantation, University of Illinois, MC958, Chicago, IL 60093, USA.
Curr Diab Rep. 2005 Aug;5(4):311-6. doi: 10.1007/s11892-005-0029-9.
Pancreatic islet transplantation has gone a long way to finally enter the armamentarium of today's clinicians for the battle against diabetes. The proof of principle has been made and current clinical islet transplant trials need to further refine this attractive treatment modality. We review the post-Edmonton era, the selection of islet transplant recipients, the production of islet grafts, and the need for immunosuppression and procedure-related risks. The success of islet transplantation and expansion of clinical trials with islet networks are also discussed.
胰岛移植已经走过了漫长的道路，最终进入了当今临床医生对抗糖尿病的武器库。原理验证已经完成，目前的临床胰岛移植试验需要进一步完善这种有吸引力的治疗方式。我们回顾了埃德蒙顿时代之后的情况、胰岛移植受者的选择、胰岛移植物的生产以及免疫抑制的必要性和与手术相关的风险。还讨论了胰岛移植的成功以及胰岛移植网络临床试验的扩展情况。
